Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis

Inga Wessels, Benjamin Rolles, Lothar Rink

Frontiers in Immunology · 2020 · Review · CC BY

doi:10.3389/fimmu.2020.01712

Abstract

During the current corona pandemic, new therapeutic options against this viral disease are urgently desired. Due to the rapid spread and immense number of affected individuals worldwide, cost-effective, globally available, and safe options with minimal side effects and simple application are extremely warranted. This review will therefore discuss the potential of zinc as preventive and therapeutic agent alone or in combination with other strategies, as zinc meets all the above described criteria. While a variety of data on the association of the individual zinc status with viral and respiratory tract infections are available, study evidence regarding COVID-19 is so far missing but can be assumed as was indicated by others and is detailed in this perspective, focusing on re-balancing of the immune response by zinc supplementation. Especially, the role of zinc in viral-induced vascular complications has barely been discussed, so far. Interestingly, most of the risk groups described for COVID-19 are at the same time groups that were associated with zinc deficiency. As zinc is essential to preserve natural tissue barriers such as the respiratory epithelium, preventing pathogen entry, for a balanced function of the immune system and the redox system, zinc deficiency can probably be added to the factors predisposing individuals to infection and detrimental progression of COVID-19. Finally, due to its direct antiviral properties, it can be assumed that zinc administration is beneficial for most of the population, especially those with suboptimal zinc status.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The importance of the trace element zinc for the development and function of the immune system across all kinds of species has been proven in numerous studies. As zinc deficiency results in altered numbers and dysfunction of all immune cells, subjects with suboptimal zinc state have an increased risk for infectious diseases, autoimmune disorders, and cancer. In addition to malnutrition, risk groups for zinc deficiency include the elderly and patients with various inflammatory and autoimmune diseases, which will be discussed in detail later in the article. As mild zinc deficiency is largely sub-clinical, it is unnoticed in most people. However, the World Health Organization (WHO) assumes that at least one third of the world population is affected by zinc deficiency. The fact that zinc deficiency is responsible for 16% of all deep respiratory infections world-wide provides a first strong hint on a link of zinc deficiency with the risk of infection and severe progression of COVID-19 and suggests potential benefits of zinc supplementation.

The most common symptoms of COVID-19 are impaired smell and taste, fever, cough, sore throat, general weakness, pain as aching limbs, runny nose, and in some cases diarrhea. In the subsequent chapters, we will associate most of those symptoms with altered zinc homeostasis and explain how zinc might prevent or attenuate those symptoms, as summarized in Figure 1, and thus should be regarded as promising cost-effective, globally available therapeutic approach for COVID-19 patients, for which minimal to no side effects are known.

Zinc Protects the Human Body From Entering of the Virus

The entry of infectious agents into the human body is prevented by tissue barriers equipped with cilia and mucus, anti-microbial peptides like lysozymes and interferons. Regarding SARS-CoV2, the angiotensin-converting enzyme 2 (ACE2) and the cellular protease TMPRSS2 are the major mechanism for entering the cells.

Mucociliar clearance of viruses is affected by zinc

Infections with coronaviruses go along with damage of the ciliated epithelium and ciliary dyskinesia consecutively impairing the mucociliar clearance. It was shown that physiological concentrations of zinc increase ciliary beat frequency. Moreover, zinc supplementation in zinc deficient rats had a positive effect on the number and the length of bronchial cilia (Figure 1.4). Improved ciliary clearance does not only improve the removal of virus particle, it also reduces the risk of secondary bacterial infections, as discussed later. Alterations of the extracellular matrix, as monitored by increased epidermal growth factor and proliferating cell nuclear antigen (PCNA) immunostaining of rat lungs during zinc deficiency have also been described.

Zinc is essential for preserving tissue barriers

Disturbances in the integrity of the respiratory epithelia facilitate the entry of the virus as well as co-infecting pathogens and can lead to pathogens entering the blood stream. An ex-vivo model of the chronic obstructive pulmonary disease (COPD) showed that decreasing zinc levels raised the leakage of the epithelium of the respiratory tract, while zinc supplementation improved lung integrity in a murine model of acute lung injury in vivo. Increased apoptosis and E-cadherin/beta-catenin proteolysis were amongst the underlying mechanisms. The expression of tight junction proteins like Claudin-1 and ZO-1 was found to be zinc-dependent, offering another explanation for zinc's positive effects on lung integrity. In addition, an inhibitory effect of zinc on LFA-1/ICAM-1 interaction weakened inflammation in the respiratory tract via reduction of leukocyte recruitment. Furthermore, high zinc levels improved the tolerance of the lung towards damage induced by mechanical ventilation (Figure 1.4).

Zinc-dependent alterations in gene expression by pneumocytes could affect viral entering

ACE-2, mainly expressed on pneumocytes type 2, is a zinc-metalloenzyme. Zinc binds to its active center and is thus essential for its enzymatic activity. If zinc binding also affects the molecular structure of ACE-2 and thereby its binding affinity to the virus, remains to be tested. However, this is likely as zinc is important for stabilizing protein structures and altering substrate affinity of various metalloproteins. Finally, zinc homeostasis might affect ACE-2 expression, as zinc-dependent expression was reported for other zinc-metalloenzyme such as metallothionein and matrix metalloproteinases. This suggestion is strengthened by the finding that ACE-2 expression is regulated by Sirt-1. As zinc decreases Sirt-1 activity, it might decrease ACE-2 expression and thus viral entry into the cell (Figure 1.2).

A lack of adequate secretion of type I and type II interferons was reported for COVID-19 patients. For human interferon alpha (IFN-α) it was shown that zinc supplementation can reconstitute its expression by leukocytes and potentiates its anti-viral effect via JAK/STAT1 signaling as observed for rhinovirus-infected cells. However, as it was suggested that SARS-CoV2 might take advantage of the interferon-dependent expression of ACE2, which was recently addressed by Ziegler et al., the overall effects of zinc need to be carefully evaluated in future studies.

Zinc Directly Inhibits Viral Replication

As a virus, SARS-CoV2 is highly dependent on the metabolism of the host cell. Direct antiviral effects of zinc have been demonstrated in various cases, which was reviewed in great detail. Examples include coronaviridae, picornavirus, papilloma virus, metapneumovirus, rhinovirus, herpes simplex virus, varicella-zoster virus, respiratory syncytial virus, human immunodeficiency virus (HIV), and the hepatitis C virus. It was suggested that zinc can prevent fusion with the host membrane, decreases the viral polymerase function, impairs protein translation and processing, blocks viral particle release, and destabilizes the viral envelope. Low-dose zinc supplementation together with small concentrations of the zinc ionophores pyrithione or hinokitol decreased RNA synthesis in influenza, poliovirus, picornavirus, the equine arteritis virus, and SARS-CoV by directly inhibiting the RNA-dependent RNA polymerase of the virus. There is evidence that zinc can enhance the effect of chloroquine, another known zinc ionophore, while zinc ionophores like epigallocatechin-gallate or quercetin remain to be tested. There are close similarities of SARS-CoV2 and other coronaviridae like SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV). Also, the alcohol-aversive drug disulfiram can bind the papain-like proteases of SARS-CoV and MERS-CoV resulting in release of cysteine-bound zinc that results in protein destabilization. Detailed studies on zinc's effect specifically on SARS-CoV2 are highly required (Figure 1.3).

Zinc Balances the Immune Response During Infectious Diseases

One of the hallmarks of COVID-19 is an imbalanced immune response. Due to hyper-inflammation, immune products including pro-inflammatory cytokines like interleukin (IL)-6, C-reactive protein (CRP), tumor necrosis factor (TNF)α and IL-1β (summarized as cytokine storm or cytokine release syndrome), reactive oxygen, and nitrogen species in connection with the recruitment of high numbers of strongly activated immune cells to the lungs, the destruction of the tissue, permanent lung damage and death due to systemic inflammation, and organ failure are expected, while the anti-inflammatory response is insufficient. A high number of patients develop an acute respiratory distress syndrome (ARDS) accompanied by high alveolar leakage leading to alveolar and interstitial edema with severely limited oxygen exchange. Advanced SARS-CoV2 infections are characterized by a systemic involvement with organ complications and accompanying cytokine storm.

There is no doubt on the anti-inflammatory and anti-oxidative properties of zinc and underlying mechanisms have been the focus of numerous studies. A detailed description of zinc metabolism in airway epithelium and during inflammation of the airways has been published by Zalewski et al.. On the other hand, zinc deficiency was associated with elevated levels of pro-inflammatory mediators, increased reactive oxygen species (ROS) levels and pre-disposing for severe progression of inflammatory diseases, especially those affecting the lung, often reversible by zinc supplementation (Figures 1.5,1.6). As one example, exposure to organic dust increased lung damage, inflammation and macrophage hyper-activation in animals with zinc deficiency, predisposing these animals to pulmonary fibrosis, while zinc supplementation 24 h before induction of acute lung injury significantly attenuated the inflammatory reaction and tissue damage. Regarding systemic inflammatory diseases the number of studies showing benefits of especially preventive zinc supplementation is constantly increasing. Amongst the underlying mechanism, zinc's role as second messenger and importance in regulating intracellular signaling as detailed in Figure 1 were described as well as zinc's effects on the epigenome.

Furthermore, leukocytosis with neutrophilia and lymphopenia, especially affecting CD8+ T cells, were associated with poor prognosis of COVID-19 and the recovery of lymphocyte counts lead to clinical recovery. Similar changes in lymphopoiesis and myelopoiesis have been described in zinc deficient rodents, which were normalized when zinc was supplemented. Circulating and lung-resident T cells from COVID-19 patients showed increased expression of markers for T cell exhaustion like Tim-3 and PD-1. The extent of these changes had an impact on the patient's prognosis. During the past decades, an immense literature was generated on the need of zinc for lymphocyte development and function and that zinc supplementation can reverse lymphopenia. Enumerating all findings and underlying mechanisms is beyond the scope of this article, and a lot of aspects have been discussed in related publications but as one of the many key roles of zinc in the context of T cell function, zinc is indispensable in the signal cascade of the T cell receptor and IL-2 as a second messenger (Figure 1.9). The B cell compartment also strongly benefits from a balanced zinc homeostasis, as zinc is required for B cell maturation and function (Figure 1.8). Also important to mention, but neglected by previous related articles, is that there is evidence that SARS-CoV2 can directly infect T cells as well as B cells and impair their cell specific function. This could explain the impact of SARS-CoV2 infection on lymphoid tissues like the human spleen and lymph nodes. However, as data are limited to in vitro experiments, this needs to be verified in vivo as well as if zinc affects the virus-induced changes in T and B cells.

Additionally, granulocytes play a vital role during the inflammation-induced destruction of the lung. Recent evidence suggests that lipopolysaccharide-induced hyper-activation, recruitment and formation of neutrophil extracellular traps are attenuated by zinc supplementation in vivo and that cytokine expression, phagocytosis and burst, chemotaxis and degranulation, and intracellular signaling are zinc regulated (Figure 1.5). Important defense mechanisms of the innate immunity include the toll like receptors. For instance, in silico data suggest that toll-like receptor (TLR)-4 can potentially recognize outer components of SARS-CoV2's like the viral spikes, while intracellular receptors including TLR3, TLR7/8, and TLR9 can recognize viral dsRNA, ssRNA, and unmethylated CpG DNA respectively. Intranasal pretreatment with a TLR3 agonist and, to a lesser extent, with TLR9, TLR7/8, or TLR4 agonists, provided a high level of protection against infections by SARS coronavirus and influence virus in mice, suggesting that TLR signaling can induce protective antiviral immunity. This might be a completely novel approach to consider regarding COVID-19 as well. Zinc is an essential regulator in TLR-4- and TLR-3-induced signaling in innate immune cells. Thus, zinc deficiency potentially disturbs the innate immune response toward SARS-CoV2, enabling the virus to easily spread throughout the host without an adequate immune response (Figure 1.6).

Clinical improvement of COVID-19 patients was correlated to an increase of CD14+ monocytes and NK cells in the recovery phase. For a physiological inflammatory response and phagocytic activity macrophages need sufficient intracellular zinc levels. In addition, for NK cells and cytotoxic T cells it was shown that zinc supplementation increased their cytotoxicity toward target cells (Figures 1.7,1.10).

In summary zinc's (re-)balancing power regarding immune cell numbers and functions might be highly beneficial in regard to therapy of COVID-19.

Zinc Supplementation in Respiratory Infections

Our suggested benefits of zinc supplementation to prevent and treat COVID-19 are supported by a row of successful supplementation studies focusing on respiratory tract infection, of which we listed some selected publications in Table 1. In most cases, prophylactic zinc supplementation was more effective than therapeutic proceedings. Up to 30% of the everyday respiratory infections, briefly named “common cold,” are due to infections with coronaviruses. Studies showed reduced symptom severity, reduced frequency, and duration of the common cold after zinc administration depending on dosage, zinc compound and the start time after initial symptoms. Most importantly, zinc supplementation of children revealed significant benefits in various studies and reduced 15% pneumonia-specific morality and 19% of pneumonia morbidity in developing countries.

Risk Groups and Symptoms of COVID-19 and Zinc Deficiency Reveal a Large Overlap

As illustrated in Figure 1.1, the intersection between risk groups of COVID-19 and zinc deficiency is impressive. In patients with chronic obstructive pulmonary disease (COPD), bronchial asthma, cardiovascular diseases, autoimmune diseases, kidney diseases, dialysis, obesity, diabetes, cancer, atherosclerosis, liver cirrhosis, immunosuppression, and known liver damage low serum zinc levels are regularly observed. At the same time, these groups are particular at risk for COVID-19. For example 57.5% elderly and nursing home residents in the U.S., for which high incidence of respiratory tract infections is described, showed significantly decreased zinc intake levels and are considered subjects with high risk regarding COVID-19. Moreover, other studies showed that serum zinc levels were inversely correlated with pneumonia and cystic fibrosis. On the other hand, zinc supplementation was able to reconstitute immune function in elderly and zinc deficient individuals, which remains to be addressed for SARS-CoV2 infections. In this regard, the low response of older patients with low serum zinc to a 23-valent pneumococcal polysaccharide vaccination compared to those with higher zinc level, should be mentioned. However, zinc's role in the response to vaccination is generally discussed controversially and no data are available for vaccination against any corona virus.

Several studies indicate that there is an association between chemosensory dysfunctions and COVID-19. Smell or taste is largely decreased, which might be a good disease biomarker. It was suggested that this might either be due to direct destruction of sensory cells by the virus, as ACE-2 is highly expressed by the oral mucosa, or by viral entry into the brain and neuronal pathologies as was described for other SARS-CoV. Zinc deficiency was related to significantly reduced taste sensitivity and impaired saliva secretion in humans and animals, which might involve zinc's importance for the action of carbonic anhydrase. Results from supplementation studies largely describe improvements in chemosensory functions, but some studies did not find any effects or even more severe disturbances when very high zinc concentrations were used. This is possibly due to investigating olfactory diseases of various origins, the lack of controlled trials and inclusion of observable studies. Thus, the benefits of zinc supplementation alone or in combination with common medical strategies should be tested for taste and smell diseases according to the available guidelines.

About 50% of patients that died of COVID-19 had bacterial or fungal co-infections, underlining the importance of sustaining the immune function by a sufficient zinc supply. In animal experiments it was shown that zinc restriction made mice highly susceptible to bacterial infection with streptococcus pneumoniae. As mentioned earlier, marginal zinc deficiency affects one third of the worldwide population and most subjects with COVID-19 are at risk of zinc deficiency (Figure 1). During physiological inflammatory responses, zinc is additionally redistributed to the tissues, resulting in serum hypozincemia. In combination with the pre-existing suboptimal zinc supply, this will decrease serum zinc levels to critically low values and thereby significantly increase the susceptibility for co-infections with detrimental progression. In critically ill patients persistent low serum zinc was associated with recurrent sepsis and serum zinc levels were inversely correlated with mortality from sepsis, underlining the potential benefits of monitoring the zinc status of the patients and implementing zinc supplementation into therapy of COVID-19.

Vascular complications resulting from atherosclerosis development, microangiopathic organ failure, and venous thromboembolism were found as a major cause of death in COVID-19 patients, suggesting an important role of disease-induced coagulopathy, which, however, needs further investigation. Zinc influences thrombocyte aggregation and coagulation. Recently, a functional association between zinc and ROS production in platelets was described, indicating that zinc could decrease thrombus formation in a clinical context. Complications of SARS-CoV2 infections also include tissue damage affecting the gastrointestinal system, the liver, heart, nervous system, kidneys, blood vessels, and the skin. In this regard it should be mentioned that a balanced zinc homeostasis is essential for wound healing and tissue recovery after mechanical and inflammation-mediated damage, adding more potential benefits of zinc supplementation of COVID-19 patients (Figure 1.11).

Conclusion

In this perspective, we reviewed the most important literature on the role of zinc homeostasis during viral infections, focusing on the potential benefits of zinc supplementation to prevent and treat SARS-CoV2 infections. Although data specifically on SARS-CoV2 are unfortunately still pending and randomized controlled studies have not been conducted, the enumerated evidence from the literature strongly suggests great benefits of zinc supplementation. Zinc supplementation improves the mucociliary clearance, strengthens the integrity of the epithelium, decreases viral replication, preserves antiviral immunity, attenuates the risk of hyper-inflammation, supports anti-oxidative effects and thus reduces lung damage and minimized secondary infections. Especially older subjects, patients with chronic diseases and most of the remaining COVID-19 risk groups would most likely benefit. Although studies are needed testing the effect of zinc as therapeutic option for established disease, preventive supplementation of subjects from risk groups should begin now, as zinc is a cost-efficient, globally available and simple to use option with little to no side effects. The first clinical trials on zinc supplementation alone and in combination with other drugs such as chloroquine have been registered. Thus, first results and treatment regimens regarding zinc supplementation for COVID-19 risk groups and patients can be anticipated soon.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Author's Note

LR is a member of ZINC Net.

Author Contributions

IW, BR, and LR drafted and corrected the text, table, and figure. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 162

  1. 1.
    Zinc as a Gatekeeper of Immune Function · 2017
    No notice
  2. 2.
    Zinc in Infection and Inflammation · 2017
    No notice
  3. 3.

    Roohani N Hurrell R Kelishadi R Schulin R. Zinc and its importance for human health: an integrative review. J Res Med Sci. (2013 ) 18:144–57.

    Not in our library

  4. 4.

    Wessels I Rink L. Micronutrients in autoimmune diseases: possible therapeutic benefits of zinc and vitamin D. J Nutr Biochem. (2020 ) 77:108240.

    Not in our library10.1016/j.jnutbio.2019.108240

  5. 5.

    Haase H Schomburg L. You'd better zinc-trace element homeostasis in infection and inflammation. Nutrients. (2019 ) 11:2078.

    Not in our library10.3390/nu11092078

  6. 6.

    Prasad AS. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis. (2000 ) 182(Suppl. 1):S62–8.

    Not in our library10.1086/315916

  7. 7.

    Suita S Ikeda K Nagasaki A Hayashida Y. Zinc deficiency during total parenteral nutrition in childhood. J Pediatric Surg. (1978 ) 13:5–9.

    Not in our library10.1016/s0022-3468(78)80202-4

  8. 8.

    Hotz C Brown KH. Identifying populations at risk of zinc deficiency: the use of supplementation trials. Nutr Rev. (2001 ) 59:80–4.

    Not in our library10.1111/j.1753-4887.2001.tb06992.x

  9. 9.

    World Health Organization The World Health report 2002. Midwifery. (2003 ) 19:72–3.

    Not in our library10.1054/midw.2002.0343

  10. 10.

    Eurosurveillance ET Updated rapid risk assessment from ECDC on coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK. Euro Surveill. (2020 ) 25:2003121

    Not in our library10.2807/1560-7917.es.2020.25.10.2003121

  11. 11.

    Hoffmann M Kleine-Weber H Krüger N Müller M Drosten C Pöhlmann S The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. (2020 ).. [Epub ahead of print].

    Not in our library10.1101/2020.01.31.929042

  12. 12.

    Chilvers MA McKean M Rutman A Myint BS Silverman M O'Callaghan C. The effects of coronavirus on human nasal ciliated respiratory epithelium. Eur Respir J. (2001 ) 18:965–70.

    Not in our library10.1183/09031936.01.00093001

  13. 13.

    Woodworth BA Zhang S Tamashiro E Bhargave G Palmer JN Cohen NA. Zinc increases ciliary beat frequency in a calcium-dependent manner. Am J Rhinol Allergy. (2010 ) 24:6–10.

    Not in our library10.2500/ajra.2010.24.3379

  14. 14.

    Darma A Athiyyah AF Ranuh RG Merbawani W Setyoningrum RA Hidajat B Zinc supplementation effect on the bronchial cilia length, the number of cilia, and the number of intact bronchial cell in zinc deficiency rats. Indones Biomed J. (2020 ) 12:78–84.

    Not in our library10.18585/inabj.v12i1.998

  15. 15.

    Biaggio VS Salvetti NR Pérez Chaca MV Valdez SR Ortega HH Gimenez MS. Alterations of the extracellular matrix of lung during zinc deficiency. Br J Nutr. (2012 ) 108:62–70.

    Not in our library10.1017/s0007114511005290

  16. 16.

    Roscioli E Jersmann HP Lester S Badiei A Fon A Zalewski P. Zinc deficiency as a codeterminant for airway epithelial barrier dysfunction in an ex vivo model of COPD. Int J Chron Obstruct Pulmon Dis. (2017 ) 12:3503–10.

    Not in our library10.2147/copd.s149589

  17. 17.

    Wessels I Pupke JT Trotha K-T von Gombert A Himmelsbach A Fischer HJ. Zinc supplementation ameliorates lung injury by reducing neutrophil recruitment and activity. Thorax. (2020 ) 75:253–61.

    Not in our library10.1136/thoraxjnl-2019-213357

  18. 18.

    Bao S Knoell DL. Zinc modulates cytokine-induced lung epithelial cell barrier permeability. Am J Physiol Lung Cell Mol Physiol. (2006 ) 291:L1132–41.

    Not in our library10.1152/ajplung.00207.2006

  19. 19.

    Fraker PJ King LE. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr. (2004 ) 24:277–98.

    Not in our library10.1146/annurev.nutr.24.012003.132454

  20. 20.

    Novick SG Godfrey JC Pollack RL Wilder HR. Zinc-induced suppression of inflammation in the respiratory tract, caused by infection with human rhinovirus and other irritants. Med Hypotheses. (1997 ) 49:347–57.

    Not in our library10.1016/s0306-9877(97)90201-2

  21. 21.

    Boudreault F Pinilla-Vera M Englert JA Kho AT Isabelle C Arciniegas AJ. Zinc deficiency primes the lung for ventilator-induced injury. JCI Insight. (2017 ) 2:e86507.

    Not in our library10.1172/jci.insight.86507

  22. 22.

    Speth R Carrera E Jean-Baptiste M Joachim A Linares A Concentration-dependent effects of zinc on angiotensin-converting enzyme-2 activity (1067.4). FASEB J. (2014 ) 28(1_supplement):1067.4.

    Not in our library

  23. 23.

    Reeves PG O'Dell BL. Effects of dietary zinc deprivation on the activity of angiotensin-converting enzyme in serum of rats and guinea pigs. J Nutr. (1986 ) 116:128–34.

    Not in our library10.1093/jn/116.1.128

  24. 24.

    Christianson DW Alexander RS Carboxylate-histidine-zinc interactions in protein structure and function. J. Am. Chem. Soc. (1989 ) 111:6412–9.

    Not in our library10.1021/ja00198a065

  25. 25.

    Cox E. Zinc-dependent protein folding. Curr Opin Chem Biol. (2000 ) 4:162–5.

    Not in our library10.1016/s1367-5931(99)00070-8

  26. 26.

    Cao J-W Duan S-Y Zhang H-X Chen Y Guo M. Zinc deficiency promoted fibrosis via ROS and TIMP/MMPs in the myocardium of mice. Biol Trace Elem Res. (2019 ) 196:145–52.

    Not in our library10.1007/s12011-019-01902-4

  27. 27.

    Rosenkranz E Metz CH Maywald M Hilgers R-D Weßels I Senff T. Zinc supplementation induces regulatory T cells by inhibition of Sirt-1 deacetylase in mixed lymphocyte cultures. Mol Nutr Food Res. (2016 ) 60:661–71.

    Not in our library10.1002/mnfr.201500524

  28. 28.

    Patel VB Zhong J-C Grant MB Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. (2016 ) 118:1313–26.

    Not in our library10.1161/circresaha.116.307708

  29. 29.

    Blanco-Melo D Nilsson-Payant BE Liu W-C Møller R Panis M Sachs D SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. bioRxiv. (2020 ).. [Epub ahead of print].

    Not in our library10.1101/2020.03.24.004655

  30. 30.

    Berg K Bolt G Andersen H Owen TC. Zinc potentiates the antiviral action of human IFN-alpha tenfold. J Interferon Cytokine Res. (2001 ) 21:471–4.

    Not in our library10.1089/10799900152434330

  31. 31.

    Cakman I Kirchner H Rink L. Zinc supplementation reconstitutes the production of interferon-alpha by leukocytes from elderly persons. J Interferon Cytokine Res. (1997 ) 17:469–72.

    Not in our library10.1089/jir.1997.17.469

  32. 32.
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues · 2020
    No notice
  33. 33.

    Ishida T Review on the role of Zn2+ ions in viral pathogenesis and the effect of Zn2+ Ions for host cell-virus growth inhibition. AJBSR. (2019 ) 2:28–37.

    Not in our library10.34297/ajbsr.2019.02.000566

  34. 34.

    Krenn BM Gaudernak E Holzer B Lanke K van Kuppeveld FJ Seipelt J. Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections. J Virol. (2009 ) 83:58–64.

    Not in our library10.1128/jvi.01543-08

  35. 35.

    Read SA Obeid S Ahlenstiel C Ahlenstiel G. The role of zinc in antiviral immunity. Adv Nutr. (2019 ) 10:696–710.

    Not in our library10.1093/advances/nmz013

  36. 36.

    Skalny AV Rink L Ajsuvakova OP Aschner M Gritsenko VA Alekseenko SI. Zinc and respiratory tract infections: perspectives for COVID19 (Review). Int J Mol Med. (2020 ) 46:17–26.

    Not in our library10.3892/ijmm.2020.4575

  37. 37.

    Suara RO Crowe JE. Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents Chemother. (2004 ) 48:783–90.

    Not in our library10.1128/aac.48.3.783-790.2004

  38. 38.

    Cai H Zhang Y Ma Y Sun J Liang X Li J. Zinc binding activity of human metapneumovirus M2-1 protein is indispensable for viral replication and pathogenesis in vivo. J Virol. (2015 ) 89:6391–405.

    Not in our library10.1128/jvi.03488-14

  39. 39.

    Lazarczyk M Favre M. Role of Zn2+ ions in host-virus interactions. J Virol. (2008 ) 82:11486–94.

    Not in our library10.1128/jvi.01314-08

  40. 40.

    Kümel G Schrader S Zentgraf H Daus H Brendel M. The mechanism of the antiherpetic activity of zinc sulphate. J Gen Virol. (1990 ) 71:2989–97.

    Not in our library10.1099/0022-1317-71-12-2989

  41. 41.
    Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture · 2010
    No notice
  42. 42.

    Shittu MO Afolami OI. Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives - a better synergy for future COVID-19 clinical trials. Infez Med. (2020 ) 28:192–7.

    Not in our library

  43. 43.

    Dabbagh-Bazarbachi H Clergeaud G Quesada IM Ortiz M O'Sullivan CK Fernández-Larrea JB. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model. J Agric Food Chem. (2014 ) 62:8085–93.

    Not in our library10.1021/jf5014633

  44. 44.
    Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020
    No notice
  45. 45.
    Chloroquine Is a Zinc Ionophore · 2014
    No notice
  46. 46.

    Liu J Zheng X Tong Q Li W Wang B Sutter K. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. (2020 ) 92:491–4.

    Not in our library10.1002/jmv.25709

  47. 47.

    Lin M-H Moses DC Hsieh C-H Cheng S-C Chen Y-H Sun C-Y. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. (2018 ) 150:155–63.

    Not in our library10.1016/j.antiviral.2017.12.015

  48. 48.
    Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing · 2020
    Corrected
  49. 49.

    Cheng ZJ Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. (2020 ) 48:155–63.

    Not in our library10.1007/s15010-020-01401-y

  50. 50.

    Chen G Di Wu Guo W Cao Y Huang D Wang H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020 ) 130:2620–9.

    Not in our library10.1172/jci137244

  51. 51.

    Guan W-J Ni Z-Y Hu Y Liang W-H Ou C-Q He J-X Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020 ) 382:1708–20.

    Not in our library10.1056/nejmoa2002032

  52. 52.

    Mehta P McAuley DF Brown M Sanchez E Tattersall RS Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020 ) 395:1033–4.

    Not in our library10.1016/s0140-6736(20)30628-0

  53. 53.

    Matthay MA Zemans RL Zimmerman GA Arabi YM Beitler JR Mercat A Acute respiratory distress syndrome. Nat Rev Dis Primers. (2019 ) 5:18

    Not in our library10.1038/s41572-019-0069-0

  54. 54.

    Wichmann D Sperhake J-P Lütgehetmann M Steurer S Edler C Heinemann A. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. (2020 ).. [Epub ahead of print].

    Not in our library10.7326/m20-2003

  55. 55.

    Beck FW Prasad AS Kaplan J Fitzgerald JT Brewer GJ. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. Am J Physiol. (1997 ) 272:E1002–7.

    Not in our library10.1152/ajpendo.1997.272.6.e1002

  56. 56.

    Wessels I Haase H Engelhardt G Rink L Uciechowski P. Zinc deficiency induces production of the proinflammatory cytokines IL-1β and TNFα in promyeloid cells via epigenetic and redox-dependent mechanisms. J Nutr Biochem. (2013 ) 24:289–97.

    Not in our library10.1016/j.jnutbio.2012.06.007

  57. 57.

    Liu M-J Bao S Gálvez-Peralta M Pyle CJ Rudawsky AC Pavlovicz RE. ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB. Cell Rep. (2013 ) 3:386–400.

    Not in our library10.1016/j.celrep.2013.01.009

  58. 58.

    Ganatra HA Varisco BM Harmon K Lahni P Opoka A Wong HR. Zinc supplementation leads to immune modulation and improved survival in a juvenile model of murine sepsis. Innate Immun. (2017 ) 23:67–76.

    Not in our library10.1177/1753425916677073

  59. 59.

    Choi S Liu X Pan Z. Zinc deficiency and cellular oxidative stress: prognostic implications in cardiovascular diseases. Acta Pharmacol Sin. (2018 ) 39:1120–32.

    Not in our library10.1038/aps.2018.25

  60. 60.

    Prasad AS Beck FW Bao B Fitzgerald JT Snell DC Steinberg JD. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr. (2007 ) 85:837–44.

    Not in our library10.1093/ajcn/85.3.837

  61. 61.

    Zalewski PD Truong-Tran AQ Grosser D Jayaram L Murgia C Ruffin RE. Zinc metabolism in airway epithelium and airway inflammation: basic mechanisms and clinical targets. a review. Pharmacol Ther. (2005 ) 105:127–49.

    Not in our library10.1016/j.pharmthera.2004.09.004

  62. 62.

    Hoeger J Simon T-P Beeker T Marx G Haase H Schuerholz T. Persistent low serum zinc is associated with recurrent sepsis in critically ill patients - a pilot study. PLoS ONE. (2017 ) 12:e0176069.

    Not in our library10.1371/journal.pone.0176069

  63. 63.

    Ibs K-H Rink L. Zinc-altered immune function. J Nutr. (2003 ) 133:1452S−6S.

    Not in our library10.1093/jn/133.5.1452s

  64. 64.

    Kahmann L Uciechowski P Warmuth S Plümäkers B Gressner AM Malavolta M. Zinc supplementation in the elderly reduces spontaneous inflammatory cytokine release and restores T cell functions. Rejuvenation Res. (2008 ) 11:227–37.

    Not in our library10.1089/rej.2007.0613

  65. 65.

    Wessels I Cousins RJ. Zinc dyshomeostasis during polymicrobial sepsis in mice involves zinc transporter Zip14 and can be overcome by zinc supplementation. Am J Physiol Gastrointest Liver Physiol. (2015 ) 309:G768–78.

    Not in our library10.1152/ajpgi.00179.2015

  66. 66.

    Besecker BY Exline MC Hollyfield J Phillips G Disilvestro RA Wewers MD. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr. (2011 ) 93:1356–64.

    Not in our library10.3945/ajcn.110.008417

  67. 67.

    Knoell DL Smith DA Sapkota M Heires AJ Hanson CK Smith LM. Insufficient zinc intake enhances lung inflammation in response to agricultural organic dust exposure. J Nutr Biochem. (2019 ) 70:56–64.

    Not in our library10.1016/j.jnutbio.2019.04.007

  68. 68.

    Bao S Liu M-J Lee B Besecker B Lai J-P Guttridge DC. Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-kappaB. Am J Physiol Lung Cell Mol Physiol. (2010 ) 298:L744–54.

    Not in our library10.1152/ajplung.00368.2009

  69. 69.

    Gruber K Maywald M Rosenkranz E Haase H Plumakers B Rink L. Zinc deficiency adversely influences interleukin-4 and interleukin-6 signaling. J Biol Regul Homeost Agents. (2013 ) 27:661–71.

    Not in our library

  70. 70.
    Zinc Signals and Immunity · 2017
    No notice
  71. 71.

    Maywald M Meurer SK Weiskirchen R Rink L. Zinc supplementation augments TGF-beta1-dependent regulatory T cell induction. Mol Nutr Food Res. (2017 ) 61:1–11.

    Not in our library10.1002/mnfr.201600493

  72. 72.

    Ollig J Kloubert V Taylor KM Rink L. B cell activation and proliferation increase intracellular zinc levels. J Nutr Biochem. (2019 ) 64:72–9.

    Not in our library10.1016/j.jnutbio.2018.10.008

  73. 73.

    Reiber C Brieger A Engelhardt G Hebel S Rink L Haase H. Zinc chelation decreases IFN-beta-induced STAT1 upregulation and iNOS expression in RAW 264.7 macrophages. J Trace Elem Med Biol. (2017 ) 44:76–82.

    Not in our library10.1016/j.jtemb.2017.05.011

  74. 74.

    Kulik L Maywald M Kloubert V Wessels I Rink L. Zinc deficiency drives Th17 polarization and promotes loss of Treg cell function. J Nutr Biochem. (2019 ) 63:11–8.

    Not in our library10.1016/j.jnutbio.2018.09.011

  75. 75.

    Chen X Ling J Mo P Zhang Y Jiang Q Ma Z Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv. (2020 ).. [Epub ahead of print].

    Not in our library10.1101/2020.03.03.20030437

  76. 76.

    Liu J Li S Liu J Liang B Wang X Wang H. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. (2020 ) 55:102763.

    Not in our library10.1016/j.ebiom.2020.102763

  77. 77.
    Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) · 2020
    No notice
  78. 78.

    Hönscheid A Rink L Haase H. T-lymphocytes: a target for stimulatory and inhibitory effects of zinc ions. Endocr Metab Immune Disord Drug Targets. (2009 ) 9:132–44.

    Not in our library10.2174/187153009788452390

  79. 79.

    Prasad AS Meftah S Abdallah J Kaplan J Brewer GJ Bach JF. Serum thymulin in human zinc deficiency. J Clin Invest. (1988 ) 82:1202–10.

    Not in our library10.1172/jci113717

  80. 80.

    Kaltenberg J Plum LM Ober-Blöbaum JL Hönscheid A Rink L Haase H. Zinc signals promote IL-2-dependent proliferation of T cells. Eur J Immunol. (2010 ) 40:1496–503.

    Not in our library10.1002/eji.200939574

  81. 81.

    King LE Fraker PJ. Variations in the cell cycle status of lymphopoietic and myelopoietic cells created by zinc deficiency. J Infect Dis. (2000 ) 182(Suppl 1):S16–22.

    Not in our library10.1086/315923

  82. 82.

    Kam YW Kien F Roberts A Cheung YC Lamirande EW Vogel L. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. (2007 ) 25:729–40.

    Not in our library10.1016/j.vaccine.2006.08.011

  83. 83.

    Jaume M Yip MS Cheung CY Leung HL Li PH Kien F Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. (2011 ) 85:10582–97.

    Not in our library10.1128/jvi.00671-11

  84. 84.

    Chen Y Feng Z Diao B Wang R Wang G Wang C The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. bioRxiv. (2020 ).. [Epub ahead of print].

    Not in our library10.1101/2020.03.27.20045427

  85. 85.

    Grommes J Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. (2011 ) 17:293–307.

    Not in our library10.2119/molmed.2010.00138

  86. 86.

    Hasan R Rink L Haase H. Zinc signals in neutrophil granulocytes are required for the formation of neutrophil extracellular traps. Innate Immun. (2013 ) 19:253–64.

    Not in our library10.1177/1753425912458815

  87. 87.

    Hasan R Rink L Haase H Chelation of free Zn(2)(+) impairs chemotaxis, phagocytosis, oxidative burst, degranulation, and cytokine production by neutrophil granulocytes. Biol Trace Elem Res. (2016 ) 171:79–88.

    Not in our library10.1007/s12011-015-0515-0

  88. 88.

    Choudhury A Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. (2020 ) 1–9.. [Epub ahead of print].

    Not in our library10.1002/jmv.25987

  89. 89.

    Bieback K Lien E Klagge IM Avota E Schneider-Schaulies J Duprex WP. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol. (2002 ) 76:8729–36.

    Not in our library10.1128/jvi.76.17.8729-8736.2002

  90. 90.

    Kurt-Jones EA Popova L Kwinn L Haynes LM Jones LP Tripp RA. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. (2000 ) 1:398–401.

    Not in our library10.1038/80833

  91. 91.

    Alexopoulou L Holt AC Medzhitov R Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. (2001 ) 413:732–8.

    Not in our library10.1038/35099560

  92. 92.

    Heil F Hemmi H Hochrein H Ampenberger F Kirschning C Akira S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. (2004 ) 303:1526–9.

    Not in our library10.1126/science.1093620

  93. 93.

    Zhao J Wohlford-Lenane C Zhao J Fleming E Lane TE McCray PB. Intranasal treatment with poly(I∙C) protects aged mice from lethal respiratory virus infections. J Virol. (2012 ) 86:11416–24.

    Not in our library10.1128/jvi.01410-12

  94. 94.

    Brieger A Rink L Haase H. Differential regulation of TLR-dependent MyD88 and TRIF signaling pathways by free zinc ions. J Immunol. (2013 ) 191:1808–17.

    Not in our library10.4049/jimmunol.1301261

  95. 95.

    Rolles B Maywald M Rink L Influence of zinc deficiency and supplementation on NK cell cytotoxicity. J Funct Foods. (2018 ) 48:322–8.

    Not in our library10.1016/j.jff.2018.07.027

  96. 96.

    Rerksuppaphol S Rerksuppaphol L. A randomized controlled trial of zinc supplementation in the treatment of acute respiratory tract infection in Thai children. Pediatr Rep. (2019 ) 11:7954.

    Not in our library10.4081/pr.2019.7954

  97. 97.

    Mahalanabis D Lahiri M Paul D Gupta S Gupta A Wahed MA Randomized, double-blind, placebo-controlled clinical trial of the efficacy of treatment with zinc or vitamin A in infants and young children with severe acute lower respiratory infection. Am J Clin Nutr. (2004 ) 79:430–6.

    Not in our library10.1093/ajcn/79.3.430

  98. 98.

    Shah UH Abu-Shaheen AK Malik MA Alam S Riaz M Al-Tannir MA. The efficacy of zinc supplementation in young children with acute lower respiratory infections: a randomized double-blind controlled trial. Clin Nutr. (2013 ) 32:193–9.

    Not in our library10.1016/j.clnu.2012.08.018

  99. 99.

    Hulisz D. Efficacy of zinc against common cold viruses: an overview. J Am Pharm Assoc. (2003 ). (2004 ) 44:594–603.

    Not in our library10.1331/1544-3191.44.5.594.hulisz

  100. 100.

    Hemilä H. Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage. JRSM Open. (2017 ) 8:2054270417694291.

    Not in our library10.1177/2054270417694291

  101. 101.

    Abdulhamid I Beck FW Millard S Chen X Prasad A. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatr Pulmonol. (2008 ) 43:281–7.

    Not in our library10.1002/ppul.20771

  102. 102.

    Malik A Taneja DK Devasenapathy N Rajeshwari K. Zinc supplementation for prevention of acute respiratory infections in infants: a randomized controlled trial. Indian Pediatr. (2014 ) 51:780–4.

    Not in our library10.1007/s13312-014-0503-z

  103. 103.

    Khera D Singh S Purohit P Sharma P Singh K Prevalence of zinc deficiency and effect of zinc supplementation on prevention of acute respiratory infections. Turk Thorac J. (2019 ) 1–14.

    Not in our library10.2139/ssrn.3273670

  104. 104.

    Martinez-Estevez NS Alvarez-Guevara AN Rodriguez-Martinez CE. Effects of zinc supplementation in the prevention of respiratory tract infections and diarrheal disease in Colombian children: A 12-month randomised controlled trial. Allergol Immunopathol. (2016 ) 44:368–75.

    Not in our library10.1016/j.aller.2015.12.006

  105. 105.

    Sazawal S Black RE Jalla S Mazumdar S Sinha A Bhan MK. Zinc supplementation reduces the incidence of acute lower respiratory infections in infants and preschool children: a double-blind, controlled trial. Pediatrics. (1998 ) 102:1–5.

    Not in our library10.1542/peds.102.1.1

  106. 106.

    Roth DE Richard SA Black RE. Zinc supplementation for the prevention of acute lower respiratory infection in children in developing countries: meta-analysis and meta-regression of randomized trials. Int J Epidemiol. (2010 ) 39:795–808.

    Not in our library10.1093/ije/dyp391

  107. 107.

    Meydani SN Barnett JB Dallal GE Fine BC Jacques PF Leka LS. Serum zinc and pneumonia in nursing home elderly. Am J Clin Nutr. (2007 ) 86:1167–73.

    Not in our library10.1093/ajcn/86.4.1167

  108. 108.

    Hasanzadeh Kiabi F Alipour A Darvishi-Khezri H Aliasgharian A Emami Zeydi A. Zinc supplementation in adult mechanically ventilated trauma patients is associated with decreased occurrence of ventilator-associated pneumonia: a secondary analysis of a prospective, observational study. Indian J Crit Care Med. (2017 ) 21:34–9.

    Not in our library10.4103/0972-5229.198324

  109. 109.

    Al-Nakib W Higgins PG Barrow I Batstone G Tyrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother. (1987 ) 20:893–901.

    Not in our library10.1093/jac/20.6.893

  110. 110.

    Kurugöl Z Akilli M Bayram N Koturoglu G. The prophylactic and therapeutic effectiveness of zinc sulphate on common cold in children. Acta Paediatr. (2006 ) 95:1175–81.

    Not in our library10.1080/08035250600603024

  111. 111.

    Singh M Das RR Zinc for the common cold. Cochrane Database Syst Rev. (2013 ) 18:CD001364

    Not in our library10.1002/14651858.cd001364.pub4

  112. 112.

    Isaacs D Flowers D Clarke JR Valman HB MacNaughton MR. Epidemiology of coronavirus respiratory infections. Arch Dis Child. (1983 ) 58:500–3.

    Not in our library10.1136/adc.58.7.500

  113. 113.

    Eby GA Davis DR Halcomb WW Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. (1984 ) 25:20–4.

    Not in our library10.1128/aac.25.1.20

  114. 114.

    Godfrey JC Conant Sloane B Smith DS Turco JH Mercer N Godfrey NJ. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res. (1992 ) 20:234–46.

    Not in our library10.1177/030006059202000305

  115. 115.

    Wang MX Win SS Pang J. Zinc supplementation reduces common cold duration among healthy adults: a systematic review of randomized controlled trials with micronutrients supplementation. Am J Trop Med Hyg. (2020 ).

    Not in our library10.4269/ajtmh.19-0718

  116. 116.
    Preventive zinc supplementation in developing countries: impact on mortality and morbidity due to diarrhea, pneumonia and malaria · 2011
    No notice
  117. 117.

    Ackland ML Michalczyk A. Zinc deficiency and its inherited disorders -a review. Genes Nutr. (2006 ) 1:41–9.

    Not in our library10.1007/bf02829935

  118. 118.

    Petrilli CM Jones SA Yang J Rajagopalan H O'Donnell LF Chernyak Y Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York city. medRxiv [Preprint]. (2020 ).. [Epub ahead of print].

    Not in our library10.1101/2020.04.08.20057794

  119. 119.

    Vishnevetsky A Levy M. Rethinking high-risk groups in COVID-19. Mult Scler Relat Disord. (2020 ) 42:102139.

    Not in our library10.1016/j.msard.2020.102139

  120. 120.

    Briefel RR Bialostosky K Kennedy-Stephenson J McDowell MA Ervin RB Wright JD. Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988-1994. J Nutr. (2000 ) 130:1367S−73S.

    Not in our library10.1093/jn/130.5.1367s

  121. 121.

    Bhat MH Mudassir Rather AB Dhobi GN Koul AN Bhat FA Zinc levels in community acquired pneumonia in hospitalized patients; a case control study. Egypt J Chest Dis Tubercul. (2016 ) 65:485–9.

    Not in our library10.1016/j.ejcdt.2015.12.020

  122. 122.

    Kamei S Fujikawa H Nohara H Ueno-Shuto K Maruta K Nakashima R. Zinc deficiency via a splice switch in zinc importer ZIP2/SLC39A2 causes cystic fibrosis-associated MUC5AC hypersecretion in airway epithelial cells. EBioMedicine. (2018 ) 27:304–16.

    Not in our library10.1016/j.ebiom.2017.12.025

  123. 123.

    Haase H Mocchegiani E Rink L. Correlation between zinc status and immune function in the elderly. Biogerontology. (2006 ) 7:421–8.

    Not in our library10.1007/s10522-006-9057-3

  124. 124.

    ClinicalTrials.gov. A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers. (2020 ). Available online at: https://ClinicalTrials.gov/show/ (accessed May 15, 2020).

    Not in our library

  125. 125.

    Yan CH Faraji F Prajapati DP Boone CE DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. (2020 ) 10:806–13.

    Not in our library10.1002/alr.22579

  126. 126.

    Yan CH Faraji F Prajapati DP Ostrander BT DeConde AS. Self-reported olfactory loss associates with outpatient clinical course in Covid-19. Int Forum Allergy Rhinol. (2020 ) 10:821–31.

    Not in our library10.1002/alr.22592

  127. 127.

    Soler ZM Patel ZM Turner JH Holbrook EH. A primer on viral-associated olfactory loss in the era of COVID-19. Int Forum Allergy Rhinol. (2020 ) 10:814–20.

    Not in our library10.1002/alr.22578

  128. 128.

    Roland LT Gurrola JG Loftus PA Cheung SW Chang JL. Smell and taste symptom-based predictive model for COVID-19 diagnosis. Int Forum Allergy Rhinol. (2020 ) 10:832–8.

    Not in our library10.1002/alr.22602

  129. 129.

    Moein ST Hashemian SM Mansourafshar B Khorram-Tousi A Tabarsi P Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. (2020 ).. [Epub ahead of print].

    Not in our library10.1002/alr.22587

  130. 130.

    Lechien JR Hopkins C Saussez S. Sniffing out the evidence; It's now time for public health bodies recognize the link between COVID-19 and smell and taste disturbance. Rhinology. (2020 ).. [Epub ahead of print].

    Not in our library10.4193/rhin20.159

  131. 131.

    Lechien JR Chiesa-Estomba CM Siati DR de Horoi M Le Bon SD Rodriguez A. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. (2020 ) 1–11.

    Not in our library10.1007/s00405-020-05965-1

  132. 132.

    Russell B Moss C Rigg A Hopkins C Papa S van Hemelrijck M. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say? Ecancermedicalscience. (2020 ) 14:ed98.

    Not in our library10.3332/ecancer.2020.ed98

  133. 133.

    Giacomelli A Pezzati L Conti F Bernacchia D Siano M Oreni L. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. (2020 ).. [Epub ahead of print].

    Not in our library10.1093/cid/ciaa330

  134. 134.

    Netland J Meyerholz DK Moore S Cassell M Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. (2008 ) 82:7264–75.

    Not in our library10.1128/jvi.00737-08

  135. 135.

    Goto T Komai M Bryant BP Furukawa Y. Reduction in carbonic anhydrase activity in the tongue epithelium and submandibular gland in zinc-deficient rats. Int J Vitam Nutr Res. (2000 ) 70:110–8.

    Not in our library10.1024/0300-9831.70.3.110

  136. 136.

    Goto T Komai M Suzuki H Furukawa Y. Long-term zinc deficiency decreases taste sensitivity in rats. J Nutr. (2001 ) 131:305–10.

    Not in our library10.1093/jn/131.2.305

  137. 137.

    Goto T Shirakawa H Furukawa Y Komai M. Decreased expression of carbonic anhydrase isozyme II, rather than of isozyme VI, in submandibular glands in long-term zinc-deficient rats. Br J Nutr. (2008 ) 99:248–53.

    Not in our library10.1017/s0007114507801565

  138. 138.

    Tanaka M Secretory function of the salivary gland in patients with taste disorders or xerostomia: correlation with zinc deficiency. Acta Otolaryngol Suppl. (2002 ) 122:134–41.

    Not in our library10.1080/00016480260046526

  139. 139.

    Russell RM Cox ME Solomons N. Zinc and the special senses. Ann Intern Med. (1983 ) 99:227–39.

    Not in our library10.7326/0003-4819-99-2-227

  140. 140.

    Sandstead HH Henriksen LK Greger JL Prasad AS Good RA. Zinc nutriture in the elderly in relation to taste acuity, immune response, and wound healing. Am J Clin Nutr. (1982 ) 36:1046–59.

    Not in our library10.1093/ajcn/36.5.1046

  141. 141.

    Heckmann SM Hujoel P Habiger S Friess W Wichmann M Heckmann JG. Zinc gluconate in the treatment of dysgeusia–a randomized clinical trial. J Dent Res. (2005 ) 84:35–8.

    Not in our library10.1177/154405910508400105

  142. 142.

    Sturniolo GC D'Inca R Parisi G Giacomazzi F Montino MC D'Odorico A. Taste alterations in liver cirrhosis: are they related to zinc deficiency? J Trace Elem Electrolytes Health Dis. (1992 ) 6:15–9.

    Not in our library

  143. 143.

    Lyckholm L Heddinger SP Parker G Coyne PJ Ramakrishnan V Smith TJ. A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders. J Pain Palliat Care Pharmacother. (2012 ) 26:111–4.

    Not in our library10.3109/15360288.2012.676618

  144. 144.

    Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften Riech- und Schmeckstörungen (017/050). (2016 ). Available online at: https://www.awmf.org/leitlinien/detail/ll/017-050.html

    Not in our library

  145. 145.
    Co-infections: potentially lethal and unexplored in COVID-19 · 2020
    No notice
  146. 146.
    Dietary zinc and the control of Streptococcus pneumoniae infection. · 2019
    Not checked
  147. 147.

    Levi M Thachil J Iba T Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. (2020 ) 7:e438–40.

    Not in our library10.1016/s2352-3026(20)30145-9

  148. 148.

    Gavriilaki E Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily. Br J Haematol. (2020 ) 189:e227–30.

    Not in our library10.1111/bjh.16783

  149. 149.

    Varga Z Flammer AJ Steiger P Haberecker M Andermatt R Zinkernagel AS. Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020 ) 395:1417–8.

    Not in our library10.1016/s0140-6736(20)30937-5

  150. 150.

    Taylor KA Pugh N. The contribution of zinc to platelet behaviour during haemostasis and thrombosis. Metallomics. (2016 ) 8:144–55.

    Not in our library10.1039/c5mt00251f

  151. 151.

    Lopes-Pires ME Ahmed NS Vara D Gibbins JM Pula G Pugh N. Zinc regulates reactive oxygen species generation in platelets. Platelets. (2020 ).. [Epub ahead of print].

    Not in our library10.1080/09537104.2020.1742311

  152. 152.

    Xiao F Tang M Zheng X Liu Y Li X Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. (2020 ) 158:1831–3.e3.

    Not in our library10.1101/2020.02.17.20023721

  153. 153.

    Zhang C Shi L Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. (2020 ) 5:428–30.

    Not in our library10.1016/s2468-1253(20)30057-1

  154. 154.

    Inciardi RM Lupi L Zaccone G Italia L Raffo M Tomasoni D. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020 ).. [Epub ahead of print].

    Not in our library10.1001/jamacardio.2020.1096

  155. 155.

    Baig AM. Updates on what ACS reported: emerging evidences of COVID-19 with nervous system involvement. ACS Chem Neurosci. (2020 ) 11:1204–5.

    Not in our library10.1021/acschemneuro.0c00181

  156. 156.
    Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection · 2021
    No notice
  157. 157.

    Galván Casas C Català A Carretero Hernández G Rodríguez-Jiménez P Fernández Nieto D Rodríguez-Villa Lario A. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. (2020 ) 183:71–7.

    Not in our library10.1111/bjd.19163

  158. 158.
    Zinc in Wound Healing Modulation · 2017
    No notice
  159. 159.

    Aydemir TB Sitren HS Cousins RJ. The zinc transporter Zip14 influences c-Met phosphorylation and hepatocyte proliferation during liver regeneration in mice. Gastroenterology. (2012 ) 142:1536–46.e5.

    Not in our library10.1053/j.gastro.2012.02.046

  160. 160.

    ClinicalTrials.gov Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation. (2020 ). Available online at: https://ClinicalTrials.gov/show/NCT04342728 (accessed May 15, 2020).

    Not in our library

  161. 161.

    ClinicalTrials.gov Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting. (2020 ). Available from: https://ClinicalTrials.gov/show/NCT04370782 (accessed May 15, 2020).

    Not in our library

  162. 162.

    ANZCTR.org.au High-Dose Intravenous Zinc (HDIVZn) As Adjunctive Therapy in COVID-19 Positive Critically Ill Patients: A Pilot Randomized Controlled Trial. (2020 ). Available online at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379579&isReview=true (accessed May 15, 2020).

    Not in our library

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.